Clinical Trials Browser

Phase 2 × OTHER × Lisaftoclax × Clear all

NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT07255963 2025-12-01

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Phase 2 Recruiting

Dendritic Cell Sarcoma, Interdigitating